Table 1 Socio-demographic and clinical characteristics by AT(N) biomarker profiles (n = 129)
A+ T– (N)– (n = 58, 45%) | A+ T+ (N)– (n = 12, 9%) | A+ T– (N)+ (n = 17, 13%) | A+ T+ (N)+ (n = 42, 33%) | p value | |
|---|---|---|---|---|---|
Variable | n/% | n/% | n/% | n/% | |
Female sex | 34/59% | 10/83% | 14/82% | 30/71% | 0.139 |
Carrier of the APOE ε4 allele | 41/71% | 8/67% | 10/59% | 34/81% | 0.340 |
Type of ChEI agent | 0.445 | ||||
Donepezil (n = 71) | 37/64% | 8/67% | 7/41% | 19/45% | |
Rivastigmine (n = 24) | 9/15% | 1/8% | 4/24% | 10/24% | |
Galantamine (n = 34) | 12/21% | 3/25% | 6/35% | 13/31% | |
Variable | Mean ± standard deviation | p value | |||
Estimated age at onset, years | 72.9 ± 7.2 | 74.5 ± 4.8 | 77.1 ± 5.7 | 70.3 ± 6.2 | 0.003 |
Estimated duration of AD at baseline, years | 3.2 ± 2.4 | 2.3 ± 1.4 | 2.2 ± 1.3 | 3.0 ± 1.9 | 0.228 |
Age at baseline, years | 76.1 ± 6.2 | 76.8 ± 4.6 | 79.2 ± 6.2 | 73.3 ± 6.0 | 0.005 |
Education, years | 10.2 ± 3.1 | 9.4 ± 1.9 | 9.1 ± 2.0 | 9.0 ± 2.0 | 0.116 |
MMSE score at baseline | 21.7 ± 3.8 | 19.5 ± 3.7 | 20.6 ± 4.6 | 20.2 ± 4.0 | 0.181 |
ADAS-cog score (0–70) at baseline | 20.8 ± 9.1 | 21.8 ± 9.9 | 20.6 ± 10.2 | 23.2 ± 9.3 | 0.633 |
IADL score at baseline | 17.2 ± 5.7 | 14.6 ± 5.9 | 15.9 ± 5.7 | 15.9 ± 4.9 | 0.403 |
PSMS score at baseline | 7.9 ± 2.9 | 7.2 ± 1.9 | 8.3 ± 3.1 | 7.4 ± 2.2 | 0.568 |
Number of concomitant medications at baseline | 3.5 ± 2.8 | 3.3 ± 3.6 | 3.5 ± 2.8 | 2.6 ± 2.1 | 0.335 |
Aβ42, ng/ml | 122 ± 22 | 116 ± 12 | 118 ± 19 | 115 ± 14 | 0.274 |
T-tau, ng/ml | 72 ± 15 | 82 ± 11 | 122 ± 19 | 155 ± 46 | < 0.001 |
P-tau, ng/ml | 30 ± 13 | 61 ± 8 | 40 ± 9 | 79 ± 24 | < 0.001 |